New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
09:37 EDTATVI, GES, WLK, IGT, MFC, LNKD, MAA, AVB, NTES, EQR, BCS, ARMH, UDR, LRE, DFS, BRE, ACM, RNST, PCS, BIIBOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AECOM Technology (ACM) upgraded to Buy from Underperform at BofA/Merrill... ARM Holdings (ARMH) upgraded to Outperform from Neutral at Credit Suisse... AvalonBay (AVB) upgraded to Buy from Neutral at UBS... BRE Properties (BRE) upgraded to Buy from Neutral at UBS... Barclays (BCS) upgraded to Neutral from Underperform at Macquarie... Biogen (BIIB) upgraded to Buy from Neutral at Citigroup... Discover (DFS) upgraded to Outperform from Neutral at Credit Suisse... Equity Residential (EQR) upgraded to Buy from Neutral at UBS... LRR Energy (LRE) upgraded to Outperform from Neutral at RW Baird... MetroPCS (PCS) upgraded to Neutral from Reduce at Nomura... NetEase.com (NTES) upgraded to Buy from Hold at Deutsche Bank... Renasant (RNST) upgraded to Buy from Hold at Wunderlich... UDR, Inc. (UDR) upgraded to Buy from Neutral at UBS... Westlake Chemical (WLK) upgraded to Neutral from Sell at UBS... New Jersey Resources (njr) upgraded to Buy from Neutral at Sidoti... Mid-America Apartment (MAA) upgraded to Buy from Neutral at Hilliard Lyons... Manulife Financial (MFC) upgraded to Sector Outperformer from Sector Performer at CIBC... Renasant (RNST) upgraded to Overweight from Equal Weight at Stephens... Guess (GES) upgraded to Outperform from Neutral at Wedbush... LinkedIn (LNKD) upgraded to Buy from Outperform at CLSA... International Game (IGT) upgraded to Buy from Hold at Argus... Activision Blizzard (ATVI) upgraded to Outperform from Neutral at Macquarie.
News For ACM;ARMH;AVB;BRE;BCS;BIIB;DFS;EQR;PCS;LRE;NTES;RNST;UDR;WLK;MAA;MFC;GES;LNKD;IGT;ATVI From The Last 14 Days
Check below for free stories on ACM;ARMH;AVB;BRE;BCS;BIIB;DFS;EQR;PCS;LRE;NTES;RNST;UDR;WLK;MAA;MFC;GES;LNKD;IGT;ATVI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 15, 2014
07:11 EDTBCSBarclays still deciding what to do with investment bank, WSJ reports
Subscribe for More Information
06:58 EDTBCSBarclays appoints Gillies as non-executive director
Barclays announced that Crawford Gillies has been appointed as a non-executive director of Barclays and will become a member of the board remuneration committee with effect from May 1. The company said, "It is intended that Crawford Gillies will succeed Sir John Sunderland as chairman of the board remuneration committee at a date to be agreed, consistent with ensuring a smooth transition."
April 14, 2014
10:02 EDTLNKDOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:46 EDTBIIBBiogen hugs support at critical technical juncture, levels to watch
Subscribe for More Information
08:42 EDTLNKDLinkedIn initiated with an Overweight at Atlantic Equities
Atlantic Equities believes the recent pullback in shares of LinkedIn has created an attractive entry point. The firm started shares with an Overweight rating and $240 price target.
07:33 EDTBIIBBiogen to present Plegridy, Tecfidera data at AAN annual meeting
Subscribe for More Information
April 11, 2014
12:42 EDTACM, EQROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:15 EDTBIIBBiogen heads for test of $280 area
The shares are heading lower after an early bounce attempt and are now just above the session low at $280.13. As noted yesterday, a break below $280 would confirm topping in the shares. Support below $280 is at $273.45. Resistance is at $285.
08:00 EDTLNKDLinkedIn remains a favorite large cap name at Piper Jaffray
Piper Jaffray says LinkedIn remains one of its favorite long-term large cap names. The firm believes investors are overlooking two new opportunities for the company: the addition of Sales Solutions and the Ad API. Piper reiterates an Overweight rating on LinkedIn with a $270 price target.
07:59 EDTATVIActivision Blizzard could be pressured by lock-up expiration, says Argus
Subscribe for More Information
07:55 EDTACMAECOM Technology downgraded to Neutral from Buy at DA Davidson
DA Davidson downgraded AECOM Technology due to valuation. Price target is $35.
06:47 EDTLNKDSamsung ups S5 incentives to fend off rivals, Bloomberg says
Subscribe for More Information
06:46 EDTEQREquity Residential downgraded to Underperform from Hold at Jefferies
Subscribe for More Information
05:45 EDTEQREquity Residential downgraded to Underperform from Hold at Jefferies
Subscribe for More Information
April 10, 2014
15:13 EDTBIIBBiogen tumbles, nearing important test of support
Subscribe for More Information
14:24 EDTARMHAmazon Web Services CTO says ARM CPUs may be considered, The Register says
Amazon (AMZN) Web Services chief technology officer Werner told The Register that the company is “always looking for efficiency” and may consider using ARM (ARMH) CPUs in the future. Vogels said another processor architecture AWS has considered is IBM's (IBM) Power, the report noted. Reference Link
10:44 EDTLNKDStocks with call strike movement; FSLR LNKD
Subscribe for More Information
09:00 EDTBIIBBiogen May volatility elevated at 43 into Q1 and revenue outlook
Subscribe for More Information
07:31 EDTBIIBBiogen names Adam Koppel as SVP, Chief Strategy Officer
Subscribe for More Information
07:08 EDTBIIBBiogen announces positive top-line efficacy, safety results from Phase 3 trial
Biogen Idec and Swedish Orphan Biovitrum AB released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy of Eloctate, an investigational recombinant factor VIII Fc fusion protein product candidate, in children with severe haemophilia A. Eloctate was generally well-tolerated and no inhibitors were detected. Efficacy analyses showed twice-weekly prophylactic dosing with Eloctate maintained low bleeding rates in children.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use